Notable Labs Retained Earnings (Accumulated Deficit) 2013-2024 | NTBLQ
Notable Labs retained earnings (accumulated deficit) from 2013 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Notable Labs Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-82 |
| 2022 |
$-71 |
| 2021 |
$-262 |
| 2020 |
$-232 |
| 2019 |
$-208 |
| 2018 |
$-189 |
| 2017 |
$-168 |
| 2016 |
$-158 |
| 2015 |
$-142 |
| 2014 |
$-127 |
| 2013 |
$-110 |
| 2012 |
$ |
Notable Labs Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-91 |
| 2024-03-31 |
$-86 |
| 2023-12-31 |
$-82 |
| 2023-09-30 |
$-299 |
| 2023-06-30 |
$-298 |
| 2023-03-31 |
$-297 |
| 2022-12-31 |
$-71 |
| 2022-09-30 |
$-291 |
| 2022-06-30 |
$-282 |
| 2022-03-31 |
$-273 |
| 2021-12-31 |
$-262 |
| 2021-09-30 |
$-253 |
| 2021-06-30 |
$-246 |
| 2021-03-31 |
$-238 |
| 2020-12-31 |
$-232 |
| 2020-09-30 |
$-225 |
| 2020-06-30 |
$-219 |
| 2020-03-31 |
$-213 |
| 2019-12-31 |
$-208 |
| 2019-09-30 |
$-202 |
| 2019-06-30 |
$-198 |
| 2019-03-31 |
$-193 |
| 2018-12-31 |
$-189 |
| 2018-09-30 |
$-185 |
| 2018-06-30 |
$-179 |
| 2018-03-31 |
$-175 |
| 2017-12-31 |
$-168 |
| 2017-09-30 |
$-174 |
| 2017-06-30 |
$-168 |
| 2017-03-31 |
$-163 |
| 2016-12-31 |
$-158 |
| 2016-09-30 |
$-153 |
| 2016-06-30 |
$-150 |
| 2016-03-31 |
$-147 |
| 2015-12-31 |
$-142 |
| 2015-09-30 |
$-139 |
| 2015-06-30 |
$-133 |
| 2015-03-31 |
$-130 |
| 2014-12-31 |
$-127 |
| 2014-09-30 |
$-122 |
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
$-110 |
| 2013-09-30 |
|
| 2012-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.000B |
|
Notable Labs Ltd. is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Notable Labs Ltd., formerly known as Vascular Biogenics Ltd., is based in FOSTER CITY, Calif.
|
